Rationale and Design of the Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR) Trial.
Sign Up to like & getrecommendations! Published in 2021 at "American heart journal"
DOI: 10.1016/j.ahj.2021.03.011
Abstract: BACKGROUND Approximately half of all women with anginal symptoms and/or signs of ischemia and no obstructive coronary artery disease (INOCA) referred for coronary angiography have elevated risk for major adverse cardiac events (MACE), poor quality… read more here.
Keywords: women ischemia; trial; trial reduce; ischemia trial ... See more keywords
Coronary endothelial dysfunction appears to be a manifestation of a systemic process: A report from the Women’s Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction (WISE-CVD) study
Sign Up to like & getrecommendations! Published in 2021 at "PLoS ONE"
DOI: 10.1371/journal.pone.0257184
Abstract: Background Coronary microvascular dysfunction (CMD) is prevalent in symptomatic women with ischemia but no obstructive coronary artery disease (INOCA). Urine albumin-creatinine ratio (UACR) is a measure of renal microvascular endothelial dysfunction. Both are predictors of… read more here.
Keywords: women ischemia; systemic process; manifestation systemic; dysfunction ... See more keywords